MARKET

ANIP

ANIP

Ani Pharmaceutic
NASDAQ

Real-time Quotes | Nasdaq Last Sale

30.52
+0.70
+2.35%
After Hours: 30.52 0 0.00% 16:09 05/26 EDT
OPEN
29.96
PREV CLOSE
29.82
HIGH
30.84
LOW
29.65
VOLUME
99.34K
TURNOVER
0
52 WEEK HIGH
60.23
52 WEEK LOW
22.73
MARKET CAP
526.37M
P/E (TTM)
-6.7494
1D
5D
1M
3M
1Y
5Y
ANI Pharmaceuticals to Present at Upcoming Healthcare Investor Conferences
BAUDETTE, Minn., May 20, 2022--ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at two upcoming conferences as follows:
Business Wire · 05/20 10:50
ANI Pharmaceuticals: Q1 Earnings Insights
  ANI Pharmaceuticals (NASDAQ:ANIP) reported its Q1 earnings results on Tuesday, May 10, 2022 at 06:50 AM. Here's what investors need to know about the announcement.
Benzinga · 05/10 12:27
ANI Pharmaceuticals (ANIP) Reports Q1 Loss, Misses Revenue Estimates
ANI (ANIP) delivered earnings and revenue surprises of -250% and 1.56%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/10 12:05
ANI Pharmaceuticals Q1 EPS $(0.12) Misses $0.09 Estimate, Sales $64.50M Miss $65.03M Estimate
ANI Pharmaceuticals (NASDAQ:ANIP) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $0.09 by 233.33 percent. This is a 111.54 percent decrease over earnings of $1.04 per share
Benzinga · 05/10 11:02
BRIEF-Ani Pharmaceuticals Reports First Quarter 2022 Results Provides Purified Cortrophin® Gel Net Revenue Guidance And Full-Year 2022 Total Company Net Revenue Guidance Of $295 Million To $315 Million
reuters.com · 05/10 10:58
ANI Pharmaceuticals Non-GAAP EPS of -$0.12 misses by $0.21, revenue of $64.48M misses by $0.55M
ANI Pharmaceuticals press release (NASDAQ:ANIP): Q1 Non-GAAP EPS of -$0.12 misses by $0.21. Revenue of $64.48M (+18.3% Y/Y) misses by $0.55M. Provides Purified Cortrophin® Gel 2022 Net Revenue guidance of $35
Seekingalpha · 05/10 10:55
Earnings Scheduled For May 10, 2022
  Companies Reporting Before The Bell • The Middleby (NASDAQ:MIDD) is expected to report quarterly earnings at $2.10 per share on revenue of $935.99 million.
Benzinga · 05/10 09:18
ANI Pharmaceuticals Reports Q1 Adjusted Loss, Higher Revenue; Sets 2022 Outlook
MT Newswires · 05/10 07:38
More
No Data
Learn about the latest financial forecast of ANIP. Analyze the recent business situations of Ani Pharmaceutic through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
66.67%Buy
33.33%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ANIP stock price target is 40.67 with a high estimate of 47.00 and a low estimate of 30.00.
High47.00
Average40.67
Low30.00
Current 30.89
EPS
Actual
Estimate
0.160.430.710.99
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 243
Institutional Holdings: 11.18M
% Owned: 64.85%
Shares Outstanding: 17.25M
TypeInstitutionsShares
Increased
51
1.24M
New
15
223.82K
Decreased
43
559.22K
Sold Out
20
671.41K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.08%
Pharmaceuticals & Medical Research
+0.41%
Key Executives
Non-Executive Chairman/Independent Director
Patrick Walsh
President/Chief Executive Officer/Director
Nikhil Lalwani
Chief Financial Officer/Senior Vice President - Finance/Secretary
Stephen Carey
Senior Vice President
Chad Gassert
Senior Vice President
Ori Gutwerg
Senior Vice President
James Marken
Chief Compliance Officer
Elizabeth Powell
Other/Director
Muthusamy Shanmugam
Other
Christopher Mutz
Other
Mary Pao
Independent Director
Robert Brown
Independent Director
Thomas Haughey
Independent Director
David Nash
Independent Director
Antonio Pera
Independent Director
Renee Tannenbaum
Independent Director
Jeanne Thoma
No Data
No Data
About ANIP
ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The Company is focused on developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, oncology products (anti-cancer), hormones and steroids, and complex formulations. The Company’s products include both branded and generic pharmaceuticals. Its generic products include Aspirin and Extended Release Dipyridamole, Bretylium Tosylate Injection USP, cholestyramine, Etodolac, Fluvoxamine, Indapamide, Nilutamide, Vancomycin and more. Its branded products include Arimidex (anastrozole) tablets, Atacand HCT Tablets, Atacand (candesartan cilexetil) Tablets, Casodex, Cortenema, Cortrophin gel, Cortrophin-Zinc, Inderal LA, Inderal XL, InnoPran XL, Lithobid, Reglan and Vancocin. It operates across three pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota and one is located in Oakville, Ontario.

Webull offers kinds of ANI Pharmaceuticals Inc stock information, including NASDAQ:ANIP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ANIP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ANIP stock methods without spending real money on the virtual paper trading platform.